Keyphrases
Hepatocellular Carcinoma
88%
Patient Survival
33%
Nuclear factor-κB
33%
Indonesia
33%
C-Jun
33%
Cyclooxygenase-2
33%
Pancreatic Ductal Adenocarcinoma
33%
Alpha-fetoprotein
33%
Specificity Protein 1
33%
Hepatocellular Carcinoma Surveillance
33%
Indonesian
33%
Systemic Therapy
33%
Sorafenib
22%
Real-world Practice
22%
Curative Treatment
22%
Hepatocellular Carcinoma Patients
19%
Cancer Mortality
15%
Cancer Causes
15%
Ultrasound
15%
Ultrasound Markers
11%
Tumor Biology
11%
Ramucirumab
11%
Cabozantinib
11%
Regorafenib
11%
Atezolizumab
11%
Antibody Targeting
11%
Lenvatinib
11%
Systemic Agents
11%
Immune Checkpoint Inhibitors
11%
Clinical Decision-making
11%
Phase III Clinical Trial
11%
Most Common Cause
11%
Prognostic Factors
11%
Clinical Evidence
11%
Tumor Marker
11%
Patient Characteristics
11%
Health Policy
11%
Treatment Options
11%
Liver Function
11%
Chronic Liver Disease
11%
Advanced Hepatocellular Carcinoma
11%
Healthcare Workers
11%
Clinical High Risk
11%
Locoregional Therapy
11%
Therapeutic Potential
11%
Monoclonal Antibody
11%
Safety Profile
11%
Patient Preference
11%
Vascular Endothelial Growth Factor
11%
Survival Benefit
11%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Transcription Factor Sp1
33%
Pancreas Adenocarcinoma
33%
Nuclear Factor
33%
Biological Marker
33%
Systemic Therapy
33%
Alpha-Fetoprotein
33%
Malignant Neoplasm
20%
Sorafenib
13%
Health Care
13%
Regorafenib
6%
Cabozantinib
6%
Ramucirumab
6%
Lenvatinib
6%
Atezolizumab
6%
Tumor Biology
6%
Tumor Marker
6%
Immune Checkpoint Inhibitor
6%
Patient Characteristics
6%
Chronic Liver Disease
6%
Liver Function
6%
Hepatitis B
6%
Prognostic Factor
6%
Clinical Trial
6%
Clinician
6%
Vasculotropin
6%
Liver Cirrhosis
6%
Sensitivity and Specificity
6%
Clinical Decision Making
6%
Monoclonal Antibody
6%
Liver Cancer
6%
Bevacizumab
6%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Biological Marker
33%
Transcription Factor Sp1
33%
Alpha Fetoprotein
33%
Pancreas Adenocarcinoma
33%
Nuclear Factor
33%
Malignant Neoplasm
20%
Sorafenib
13%
Tumor Marker
6%
Ramucirumab
6%
Lenvatinib
6%
Neoplasm
6%
Regorafenib
6%
Cabozantinib
6%
Atezolizumab
6%
Liver Cirrhosis
6%
Hepatitis B
6%
Liver Cancer
6%
Vasculotropin
6%
Immune Checkpoint Inhibitor
6%
Monoclonal Antibody
6%
Chronic Liver Disease
6%
Bevacizumab
6%
Clinical Trial
6%
